Skip to content

Clinical Study of Shanggan Granules in Treating Mild Influenza

Clinical Study of Shang gan Granules in Treating Mild Influenza

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034975
Enrollment
Unknown
Registered
2020-07-26
Start date
2020-08-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza (mild)

Interventions

Sponsors

Institute of Traditional Chinese Medicine and Clinical Medicine, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Those who meet the diagnostic criteria of clinically diagnosed cases and/or confirmed cases of Western medicine for influenza; 2. Those who meet the criteria of TCM syndrome differentiation for influenza (mild); 3. Acute respiratory tracts such as stuffy nose, runny nose, sore throat, cough, etc. Symptoms and/or accompanied by fever (formally measured axillary temperature of more than 5 minutes >= 37.5 degrees C, < 39.0 degrees C; 4. Age 14-70 years. 5. Course of disease <= 48 hours. 6. Previous physical fitness, no diseases other than influenza Diagnosis history and related medication history; 7. Voluntarily participating in this study and signing informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed with tuberculosis, measles and AIDS combined with pneumocystis and other infectious diseases; 2. Those who are known to be allergic to the Chinese medicine ingredients or Western medicine used in this study; 3. Serious basic diseases such as heart, brain, lung, liver, kidney and blood system, such as patients with viral hepatitis, hemophilia, and psychosis; 4. patients with immunodeficiency or taking immunosuppressive agents or glucocorticoids within the past 3 months; 5. Before taking treatment, other internal medicines against the disease have been received, such as antiviral drugs, antibiotics, traditional Chinese medicine, etc.; 6. Those who have been vaccinated with influenza vaccine within 3 months before the consultation; 7. Pregnancy or puerperium women, unstable living environment, work place Patients who are likely to cause loss of follow-up due to frequent changes, or others who are unable or unwilling to cooperate; 8. Participate in other trials in the past 3 months.

Design outcomes

Primary

MeasureTime frame
TCM syndromes;Influenza A and B virus nucleic acid detection;

Countries

China

Contacts

Public ContactAo Suhua

Affiliated Chinese Medicine Hospital of Southwest Medical University

463787216@qq.com+86 13550898592

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026